{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-042967","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.629010+00:00","generated_at":"2026-05-21T09:20:07.710641+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Unicycive reports Q1 net income $0.5M, cash $19.8M, OLC PDUFA June 28, 2025","bullets":["Net income attributable to common stockholders of $0.5M for Q1 2025, vs net loss of $21.2M in Q1 2024.","Cash and cash equivalents totaled $19.8M as of March 31, 2025.","OLC NDA under FDA review with PDUFA target action date of June 28, 2025; commercial launch preparation ongoing.","R&D expenses fell to $2.2M from $6.8M; G&A rose to $5.8M from $2.4M due to launch prep costs.","Patient survey data presented at NKF and ANNA meetings identified pill burden as primary adherence barrier."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-042967","json":"https://secwatch.observer/filing/0001213900-25-042967.json","markdown":"https://secwatch.observer/filing/0001213900-25-042967.md","text":"https://secwatch.observer/filing/0001213900-25-042967.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/0001213900-25-042967-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/ea0242081-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:20:07.710641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}